Imatinib Lek-Am

Imatinib, the active ingredient in Imatinib Lek-Am, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, gastrointestinal stromal tumor, dermatofibrosarcoma protuberans and systemic mastocytosis in appropriate patients.

GNH USA supplies Imatinib Lek-Am as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT or PDGFR signaling pathways, providing targeted therapy for several hematologic and solid tumours. - Chronic myeloid leukemia (CML): improves survival by inhibiting BCR‑ABL‑driven proliferation. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission through BCR‑ABL blockade. - Gastrointestinal stromal tumor (GIST): reduces tumor growth by targeting c‑KIT. - Dermatofibrosarcoma protuberans (DFSP): shrinks lesions via PDGFR inhibition. - Systemic mastocytosis: controls disease activity by suppressing aberrant mast cell signaling.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea - Peripheral edema - Fatigue - Diarrhea

Serious or Rare Side Effects: - Severe neutropenia or leukopenia - Hepatotoxicity (elevated transaminases) - Cardiac failure or reduced left‑ventricular function

Careful monitoring and patient education are essential when using Imatinib. - Monitor blood counts regularly: watch for neutropenia and anemia. - Assess liver function before and during therapy: detect hepatotoxicity early. - Evaluate cardiac status in patients with pre‑existing heart disease. - Avoid use in individuals with known hypersensitivity to Imatinib or its excipients. - Store at below 25°C: keep in the original pack, protect from moisture.

Imatinib can interact with several concomitant medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase Imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce therapeutic levels.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Diuretics (e.g., furosemide): increased risk of fluid retention. - QT‑prolonging agents (e.g., quinidine): monitor cardiac rhythm.